Prevention and treatment of parathyroid hyperfunction or hyperparathyroidism associated osteoporosis
10.3760/cma.j.cn.115807-20220811-00218
- VernacularTitle:关注甲状旁腺功能增强或亢进相关骨质疏松症的防治
- Author:
Lingquan KONG
1
;
Chenyu MA
;
Ruiling SHE
;
Fan LI
;
Fajin LYU
;
Hongyuan LI
;
Kainan WU
Author Information
1. 重庆医科大学附属第一医院乳腺甲状腺外科，重庆 400016
- Keywords:
Calcium and/or vitamin D insufficiency;
Parathyroid hyperfunction;
Hyperparathyroidism;
Subclinical hyperparathyroidism;
Osteoporosis;
Osteopenia;
Parathyro
- From:
Chinese Journal of Endocrine Surgery
2022;16(4):385-390
- CountryChina
- Language:Chinese
-
Abstract:
Osteoporosis (OP) is a common systemic bone disease which has become a serious public health problem in China. In clinical practice, we found that some primary osteoporosis may be due to parathyroid hyperfunction (subclinical hyperparathyroidism) or hyperparathyroidism which is the result of negative calcium balance and hypocalcemia caused by insufficient calcium intake and/or vitamin D deficiency/insufficiency, which is preventable and controllable. Therefore, we call this kind of osteoporosis parathyroid hyperfunction or hyperparathyroidism associated osteoporosis. The daily calcium intake of Chinese people is generally insufficient, and vitamin D deficiency/insufficiency is also a worldwide public health problem. Parathyroid hyperfunction or hyperparathyroidism associated osteopenia and osteoporosis which are results of hypocalcemia and negative calcium balance caused by long-term insufficient calcium intake and/or vitamin D deficiency/insufficiency exist extensively in clinical practice. Its prevention and treatment can effectively prevent and treat osteopenia and osteoporosis, so as to effectively prevent and treat diseases such as short stature, rachiokyphosis, backache, fatigue, bone pain, fracture, metastatic vascular calcification and systemic calcinosis, improve people’s health and help achieve the goal of "Healthy China 2030" .
